CatalogResearchCommunityTools
Research & Educational Use Only. This protocol guide is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before beginning any research protocol.
Mitochondrial-Derived Peptide Evidence Grade: B (Strong Preclinical + Early Human Data)

Humanin Protocol Guide

Humanin is a 24-amino acid mitochondrial-derived peptide (MDP) encoded by the MT-RNR2 gene in mitochondrial DNA. Discovered through its ability to protect neurons from amyloid-beta toxicity associated with Alzheimer's disease, Humanin is now recognized as a key retrograde signaling molecule linking mitochondrial function to cellular survival. It activates the STAT3 pathway via the CNTFR/WSX-1/gp130 trimeric receptor, inhibits apoptosis through BAX interaction, improves insulin sensitivity via IGFBP-3 binding, and reduces inflammatory cytokines. The potent analog HNG (S14G-Humanin) is approximately 1000x more bioactive.

Protocol Overview

Compound
Humanin (HN) / HNG (S14G-Humanin analog)
Category
Mitochondrial-Derived Peptide (MDP)
Mechanism
STAT3 activation via trimeric receptor, BAX-mediated anti-apoptosis, IGFBP-3 binding for insulin sensitization, ROS reduction
Sequence
24 amino acids (MAPRGFSCLLLLTSEIDLPVKRRA)
Half-Life
~30 minutes (native); HNG analog has improved stability
Vial Size
5mg lyophilized powder (typical)
Route
Subcutaneous injection
Frequency
Once daily
Cycle Length
4-12 weeks

Dosing Protocol

ProtocolDoseFrequencyRouteDuration
HNG Conservative1-2 mcgOnce dailySubcutaneous4-8 weeks
HNG Standard5-10 mcgOnce dailySubcutaneous8-12 weeks
Native Humanin1-2 mgOnce dailySubcutaneous4-8 weeks
Native Humanin High2-4 mgOnce dailySubcutaneous4-8 weeks

Key principle: HNG (S14G-Humanin) is the preferred research form due to 1000x greater potency. Native Humanin requires milligram dosing while HNG works in the microgram range. Administer on an empty stomach in the morning.

Reconstitution Instructions

Materials Needed

  • Humanin or HNG lyophilized vial
  • Bacteriostatic water (1-2mL)
  • 3mL mixing syringe (18-20ga)
  • Insulin syringes (29-31ga) for dosing
  • Alcohol swabs

Reconstitution Steps (5mg HNG vial)

  1. Clean vial stopper with alcohol
  2. Draw 1mL bacteriostatic water
  3. Inject slowly down the vial wall
  4. Gently swirl (never shake)
  5. Wait 5 minutes for full dissolution
  6. Concentration: 5,000 mcg/mL
Dose (HNG)Volume (1mL recon)Insulin Syringe
1 mcg0.0002 mL~0.02 units (use serial dilution)
5 mcg0.001 mL0.1 units (use serial dilution)
10 mcg0.002 mL0.2 units (use serial dilution)
50 mcg0.01 mL1 unit

Note: Due to very small dosing volumes for HNG, serial dilution may be required. Reconstitute to a more dilute concentration (e.g., 50mcg/mL) for practical dosing accuracy.

Administration Guide

Injection Sites

  • Primary: Abdomen (2 inches from navel)
  • Alternate: Anterior thigh
  • Alternate: Upper arm (deltoid region)
  • Rotate injection sites daily

Timing & Storage

  • Timing: Morning on empty stomach preferred
  • Storage (lyophilized): -20°C for long-term, 2-8°C short-term
  • Storage (reconstituted): Refrigerate 2-8°C, use within 14 days
  • Protect from light and repeated freeze-thaw cycles

Expected Timeline

Week 1-2
Humanin begins accumulating systemically. Subtle improvements in energy, sleep quality, and cognitive clarity may emerge. Anti-inflammatory signaling activates.
Week 3-4
Measurable reductions in inflammatory markers (CRP, IL-6). Improved insulin sensitivity markers. Neuroprotective effects becoming established.
Week 5-8
Significant cognitive improvements in research models. Enhanced mitochondrial function and reduced oxidative damage. Improved metabolic parameters.
Week 9-12
Peak neuroprotective and metabolic benefits. Sustained improvements in cognitive function, insulin sensitivity, and cellular stress resilience. Protocol completion for most objectives.

Side Effects & Monitoring

Common Side Effects

  • Injection site irritation (mild)
  • Mild headache (transient)
  • Slight fatigue during initial days (uncommon)

Humanin has shown an excellent safety profile in preclinical studies. Endogenous levels decline naturally with age, and supplementation restores physiological signaling.

Precautions

  • Limited human clinical trial data available
  • May affect blood glucose - monitor if diabetic
  • Not recommended during pregnancy or breastfeeding
  • Theoretical concern with tumor cell cytoprotection - avoid with active malignancy

Stacking Recommendations

Compatible Compounds

  • MOTS-c: Fellow MDP for complementary metabolic benefits
  • SS-31: Cardiolipin stabilizer for synergistic mitochondrial support
  • Selank: Anxiolytic peptide for cognitive optimization stack
  • Epithalon: Telomerase activator for longevity protocol
  • NAD+ precursors: Support mitochondrial NAD+ pool

Popular Stacks

  • Longevity MDP Stack: Humanin + MOTS-c + SS-31
  • Neuroprotection: Humanin + Selank + Semax
  • Metabolic Health: Humanin + MOTS-c + NAD+

Blood Work Recommendations

PanelMarkersTiming
Basic PanelCBC, CMPBaseline, Week 6, Week 12
MetabolicFasting glucose, insulin, HbA1c, HOMA-IRBaseline, Week 6, Week 12
InflammatoryCRP, IL-6, TNF-alphaBaseline, Week 6
Oxidative Stress8-OHdG, F2-isoprostanesBaseline, Week 8
Cognitive (optional)BDNF, NGFBaseline, Week 8

Metabolic panels (fasting glucose, insulin, HOMA-IR) are the most practical tracking markers for Humanin protocols, given its well-documented insulin-sensitizing effects.

★ OFFICIAL SPONSOR
BioRoot AI
Free Functional Assessment
AI-powered root cause analysis & care plan
Start Free
Paid partnership · Learn more

Related Resources

Thymosin Alpha 1 Protocol SS-31 Protocol Thymalin Protocol Dosing Calculator Reconstitution Calculator Bloodwork Planner Stack Checker Peptide Catalog
Share & Save
𝕏 Share on Twitter 📱 Share on Reddit 💬 WhatsApp ✉️ Email 🔗 Copy Link 🖨️ Print / Save PDF Save to Favorites